Provided by Tiger Fintech (Singapore) Pte. Ltd.

Dermata Therapeutics Inc

5.20
+0.01000.19%
Post-market: 5.15-0.0500-0.96%16:40 EDT
Volume:23.08K
Turnover:120.14K
Market Cap:3.54M
PE:-0.12
High:5.38
Open:5.19
Low:5.10
Close:5.19
52wk High:23.70
52wk Low:4.59
Shares:681.56K
Float Shares:459.20K
Volume Ratio:0.69
T/O Rate:5.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-42.3158
EPS(LYR):-80.3223
ROE:-231.27%
ROA:-110.91%
PB:0.63
PE(LYR):-0.06

Loading ...

Dermata Therapeutics Presents Promising Phase 3 Trial Results

TIPRANKS
·
Sep 17

BUZZ-U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy

Reuters
·
Sep 11

BUZZ-Dermata Therapeutics climbs on acne product shift

Reuters
·
Sep 10

Dermata Therapeutics Inc - to Prioritize Development, Distribution of Otc Pharmaceutical Dermatology Products

THOMSON REUTERS
·
Sep 10

BRIEF-Dermata Withdraws FDA Application for Xyngari, Shifts Focus to OTC Skin Care

Reuters
·
Sep 10

Dermata Therapeutics : Plans to Launch Its Initial Acne Kit in Middle of 2026 With Additional Product Candidates Anticipated to Follow

THOMSON REUTERS
·
Sep 10

Dermata Therapeutics : Strategic Pivot to Prioritize Development and Distribution of Otc Pharmaceutical Dermatology Focused Products

THOMSON REUTERS
·
Sep 10

Dermata Therapeutics Inc: Has Withdrawn Its Investigational New Drug Application for Xyngari With U.S. Food and Drug Administration

THOMSON REUTERS
·
Sep 10

Dermata Therapeutics Regains Nasdaq Compliance Following Stock Consolidation

Reuters
·
Aug 26

Dermata Therapeutics Is Maintained at Buy by Maxim Group

Dow Jones
·
Aug 22

Dermata Therapeutics Q2 EPS $(1.66) Beats $(2.90) Estimate

Benzinga
·
Aug 14

Dermata Therapeutics Announces Positive Results from XYNGARI™ Phase 3 STAR-1 Clinical Trial for Acne Treatment

Reuters
·
Aug 14

Dermata Therapeutics Announces 1:10 Reverse Stock Split Effective August 1, 2025

Reuters
·
Jul 30

Dermata Therapeutics Inc. Conducted Annual Stockholders Meeting

Reuters
·
Jul 16

Dermata Therapeutics Announces Grant of Australian Patent for Innovative Hyperhidrosis Treatment

Reuters
·
Jul 08

Dermata Therapeutics Inc. Faces Nasdaq Delisting Risk Due to Non-Compliance with Minimum Bid Price Rule

Reuters
·
Jul 08

Dermata Therapeutics Inc. Unveils Corporate Presentation Highlighting Breakthroughs in Topical Dermatology Treatments

Reuters
·
Jun 11

Dermata Therapeutics Inc. Appoints Baker Tilly as New Certifying Accountant Following Merger

Reuters
·
Jun 06

Dermata Therapeutics Is Maintained at Buy by Maxim Group

Dow Jones
·
May 21

BRIEF-Dermata Therapeutics Inc - Potential NDA Filing For Xyngari In H1 2028 - SEC Filing

Reuters
·
May 21